PL3844162T3 - Inhibitory integryny alfa v beta 6 - Google Patents

Inhibitory integryny alfa v beta 6

Info

Publication number
PL3844162T3
PL3844162T3 PL19873423.8T PL19873423T PL3844162T3 PL 3844162 T3 PL3844162 T3 PL 3844162T3 PL 19873423 T PL19873423 T PL 19873423T PL 3844162 T3 PL3844162 T3 PL 3844162T3
Authority
PL
Poland
Prior art keywords
inhibitors
alpha
beta6 integrin
beta6
integrin
Prior art date
Application number
PL19873423.8T
Other languages
English (en)
Inventor
Bryce A. Harrison
James E. Dowling
Aleksey I. Gerasyuto
Matthew G. Bursavich
Dawn M. Troast
Blaise S. LIPPA
Bruce N. Rogers
Cheng Zhong
Fu-Yang Lin
Brian SOSA
Andrea Bortolato
Mats A. Svensson
Eugene Hickey
Kyle D. Konze
Tyler DAY
Byungchan Kim
Original Assignee
Morphic Therapeutic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic, Inc. filed Critical Morphic Therapeutic, Inc.
Publication of PL3844162T3 publication Critical patent/PL3844162T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL19873423.8T 2018-08-29 2019-08-29 Inhibitory integryny alfa v beta 6 PL3844162T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862724397P 2018-08-29 2018-08-29
PCT/US2019/048734 WO2020081154A1 (en) 2018-08-29 2019-08-29 INHIBITORS OF ανβ6 INTEGRIN

Publications (1)

Publication Number Publication Date
PL3844162T3 true PL3844162T3 (pl) 2025-06-09

Family

ID=70284760

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19873423.8T PL3844162T3 (pl) 2018-08-29 2019-08-29 Inhibitory integryny alfa v beta 6

Country Status (17)

Country Link
US (1) US20230242524A1 (pl)
EP (1) EP3844162B1 (pl)
AR (1) AR116036A1 (pl)
DK (1) DK3844162T3 (pl)
ES (1) ES3018512T3 (pl)
FI (1) FI3844162T3 (pl)
HR (1) HRP20250289T1 (pl)
HU (1) HUE071053T2 (pl)
LT (1) LT3844162T (pl)
PL (1) PL3844162T3 (pl)
PT (1) PT3844162T (pl)
RS (1) RS66733B1 (pl)
SI (1) SI3844162T1 (pl)
SM (1) SMT202500129T1 (pl)
TW (2) TWI835840B (pl)
UY (1) UY38352A (pl)
WO (1) WO2020081154A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201835078A (zh) 2017-02-28 2018-10-01 美商萊築理公司 αvβ6整合蛋白之抑制劑
AU2018227417B2 (en) 2017-02-28 2021-12-23 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
EP4086254B1 (en) 2018-08-29 2024-12-18 Morphic Therapeutic, Inc. Integrin inhibitors
CN120957721A (zh) * 2023-02-14 2025-11-14 莫菲克医疗股份有限公司 抑制αvβ8整合素

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
DE69829996T2 (de) * 1997-12-17 2006-02-23 Merck & Co., Inc. (A New Jersey Corp.) Integrin-rezeptor-antagonisten
JP2003502373A (ja) * 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3259271B1 (en) * 2015-02-19 2021-05-05 SciFluor Life Sciences, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
DE102016003731A1 (de) * 2016-03-24 2017-09-28 Friedrich-Alexander-Universität Erlangen-Nürnberg Verfahren zum Erzeugen eines Kompositmaterials mit hierarchischer Porosität
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TW201835078A (zh) 2017-02-28 2018-10-01 美商萊築理公司 αvβ6整合蛋白之抑制劑

Also Published As

Publication number Publication date
RS66733B1 (sr) 2025-05-30
TW202019928A (zh) 2020-06-01
HRP20250289T1 (hr) 2025-05-09
WO2020081154A1 (en) 2020-04-23
UY38352A (es) 2020-03-31
EP3844162A1 (en) 2021-07-07
DK3844162T3 (da) 2025-03-03
TWI835840B (zh) 2024-03-21
HUE071053T2 (hu) 2025-07-28
EP3844162B1 (en) 2025-01-01
TW202528309A (zh) 2025-07-16
TW202423925A (zh) 2024-06-16
EP3844162A4 (en) 2022-05-25
FI3844162T3 (fi) 2025-03-27
TWI857918B (zh) 2024-10-01
US20230242524A1 (en) 2023-08-03
ES3018512T3 (es) 2025-05-16
AR116036A1 (es) 2021-03-25
PT3844162T (pt) 2025-03-28
LT3844162T (lt) 2025-05-26
SI3844162T1 (sl) 2025-06-30
SMT202500129T1 (it) 2025-05-12

Similar Documents

Publication Publication Date Title
IL280782A (en) Inhibiting αv β6 integrin
IL270844A (en) Novel inhibitors of MAP4K1
IL270490B (en) kras g12c inhibitors and methods of using them
IL268947A (en) Inhibitors of (alpha-v)(beta-6) integrin
PL4045039T3 (pl) Hamowanie ludzkiej integryny alfa-4beta-7
IL274504A (en) 2ACSS inhibitors and methods of their use
EP3268369A4 (en) Anti-alphavbeta1 integrin inhibitors and methods of use
IL282350A (en) Bernani-RGMC inhibitors and their use
IL272649A (en) AHR inhibitors and their uses
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL287751A (en) kcnt1 inhibitors and methods of use
IL287768A (en) kcnt1 inhibitors and methods of use
EP3572400C0 (en) Ezh2 inhibitor and use thereof
PL3700902T3 (pl) Inhibitory trpc6
IL287973A (en) acss2 inhibitors and methods of their use
PT3621694T (pt) Inibidores de lrrc33 e sua utilização
IL280051A (en) EP4 inhibitors and their synthesis
IL274425A (en) Pyrrolopyrazine derivatives as alpha five integrin inhibitors
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
ZA201701852B (en) Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
PL3844162T3 (pl) Inhibitory integryny alfa v beta 6
SG11202000621VA (en) Inhibitors of ror?
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
GB201908884D0 (en) Inhibitors and use